All Posts By

Smartkarma Daily Briefs

Daily Brief ECM: Leapmotor IPO – Peers Recent Down Move Won’t Help and more

By | Daily Briefs, ECM

In today’s briefing:

  • Leapmotor IPO – Peers Recent Down Move Won’t Help
  • Leapmotor IPO: Valuation Insights
  • WCP IPO: Order Table, Revised Terms, & Passive Flow Schedule
  • Leapmotor IPO: Stuck in the Middle
  • Socionext Pre-IPO Peer Comparison – Margins Have Been Weaker than Peers, but Gap Has Been Closing
  • Onewo Space-Tech IPO Valuation Analysis
  • CALB IPO: What’s It Worth?
  • Mankind Pharma Pre-IPO Tearsheet
  • Tencent Music – Earnings Show Recovery but Do Not Rush to Make an Entry
  • GoDaddy Inc: Initiation of Coverage – Business Strategy

Leapmotor IPO – Peers Recent Down Move Won’t Help

By Sumeet Singh

  • Leapmotor (LM) aims to raise around US$1.0bn in its Hong Kong IPO. LM is a smart EV company based in China, founded in 2015.
  • As of end Jun 22, it had delivered a total of 104,829 cars with most of its sales coming from its mini units, T03.
  • In this note, we will run the deal through our ECM framework and talk about valuations.

Leapmotor IPO: Valuation Insights

By Arun George


WCP IPO: Order Table, Revised Terms, & Passive Flow Schedule

By Sanghyun Park

  • WCP’s institutional subscription rate was 33.28 to 1, one of the lowest for an IPO this size. And nearly all orders sit below the lower end.
  • WCP set the price at ₩60,000, even lower than the floor, at an implied market cap of ₩2T. And the issuer also reduced the offering volume from 9M to 7.2M. 
  • Passive flows equivalent to about 3% of SO will likely flow into WCP by March next year. It is substantial enough to consider designing a flow trade setup.

Leapmotor IPO: Stuck in the Middle

By Shifara Samsudeen, ACMA, CGMA

  • Leapmotor (2007699D HK) is a leading smart EV company in China that designs and builds EVs. The company develops key hardware, software and all electronic components of the vehicles internally.
  • The company has filed for an IPO on the HKEx and plans to raise about US$1bn through the IPO.
  • In this insight, we analyse the company’s financials to understand the key reason behind the absence of gross profit margins compared to other players in the market.

Socionext Pre-IPO Peer Comparison – Margins Have Been Weaker than Peers, but Gap Has Been Closing

By Clarence Chu

  • Socionext (6526 JP) is looking to raise up to US$285m in its Japan IPO.  
  • Socionext is a fabless semiconductor provider which commenced operations after integrating the system on a chip (SoC) businesses of Fujitsu Semiconductor Limited and Panasonic Holding Corporation.
  • In this note, we undertake a peer comparison with its international peers, which have a similar fabless business model-type to that of Socionext’s

Onewo Space-Tech IPO Valuation Analysis

By Douglas Kim

  • Onewo Space-Tech (ONEWO HK) has provided its IPO price range of HK$47.1 to HK$52.7 a piece in the IPO offering of 116.74 million shares, representing 10% of its outstanding shares.
  • Our base case valuation of Onewo Spacetech is HKD27.7 per share, which represents 41% lower than the low end of the IPO price of HKD47.1 per share. 
  • Our valuation analysis suggests a range of HKD25 per share to HKD33.5 per share. We would AVOID this deal due to the much lower target price relative to IPO price.

CALB IPO: What’s It Worth?

By Arun George


Mankind Pharma Pre-IPO Tearsheet

By Ethan Aw

  • Mankind Pharma Ltd (6596876Z IN) is looking to raise about US$1bn in its upcoming India IPO. The deal will be run by Kotak, Axis Capital, IIFL Securities, Jefferies and JPM. 
  • Mankind Pharma (MK) is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various therapeutic areas, as well as several consumer healthcare products. 
  • It is mainly focused on the domestic market. 18 of its brands were among the 300 highest selling brands in the Indian Pharmaceutical Market (IPM), according to IQVIA.

Tencent Music – Earnings Show Recovery but Do Not Rush to Make an Entry

By Shifara Samsudeen, ACMA, CGMA

  • TME’s shares are due to start trading on HKEx tomorrow once it carries out a secondary listing by introduction. The company neither issues new shares nor raise any proceeds.
  • The company’s earnings growth has started decelerating with having to end exclusive music licensing agreements with WMG, UMG and Sony Music a year ago as part of a SAMR probe.
  • TME’s 2Q2022 results show recovery in its earnings, however, we would recommend waiting until regulatory crackdown on tech platforms eases off.

GoDaddy Inc: Initiation of Coverage – Business Strategy

By Baptista Research

  • This is our first report on cloud-based solutions provider, GoDaddy.
  • The company is one of the largest players in the domains, hosting and other related cloud-based solutions space across the globe.
  • This quarter, the company launched its beta WooSaas solution, allowing it to reach larger customers.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Technical Analysis: Tencent Nearing Our Bear Target to Reverse from Short to Long and more

By | Daily Briefs, Technical Analysis

In today’s briefing:

  • Tencent Nearing Our Bear Target to Reverse from Short to Long

Tencent Nearing Our Bear Target to Reverse from Short to Long

By Thomas Schroeder

  • Tencent short from 395 is nearing our 282/264 target zone where we see a low to reverse to long as bull divergence matures.
  • Tencent 282/264 buy zone (cycle low due in early October) targets 335 once back above 310.
  • MACD bull divergence is more constructive and warns of an upside surprise in 2023 (after a Q1 decline) to challenge 395/400 macro pivot resistance.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Thematic (Sector/Industry): Japan Telecoms – MIC Reports Telecom Subscription Data Including a Key 5G Milestone and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Japan Telecoms – MIC Reports Telecom Subscription Data Including a Key 5G Milestone

Japan Telecoms – MIC Reports Telecom Subscription Data Including a Key 5G Milestone

By Kirk Boodry

  • 5G-Capable devices now account for 25% of total devices in Japan. So far, 5G take-up appears to be quicker than 4G although that doesn’t translate into higher revenue
  • MVNO subscriptions continue to grow despite former leader Rakuten moving users to its own network. IIJ remains the segment leader
  • Rakuten Mobile’s subscriber woes have been well-flagged but another issue may be ahead as the migration of MVNO subs to the MNO platform has slowed in recent quarters.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Macro: CX Daily: The Double Squeeze on China’s ‘Sandwich Generation’ and more

By | Daily Briefs, Macro

In today’s briefing:

  • CX Daily: The Double Squeeze on China’s ‘Sandwich Generation’
  • CX Daily: How China’s Insurance Industry Is Slowly Opening to the Ill

CX Daily: The Double Squeeze on China’s ‘Sandwich Generation’

By Caixin Global

  • Cover Story: The double squeeze on China’s ‘sandwich generation’.

  • Covid quarantine bus crash kills 27 in Guizhou province.

  • CDC expert warns of potential monkeypox outbreak as first case hits mainland.


CX Daily: How China’s Insurance Industry Is Slowly Opening to the Ill

By Caixin Global

  • In Depth: How China’s insurance industry is slowly opening to the ill

  • Officials probed after fatal crash of bus traveling to Covid quarantine facility

  • Hong Kong may scrap hotel quarantines and pre-arrival tests


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Equity Bottom-Up: Nexon (3659) | The Best Pipeline Ever and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • Nexon (3659) | The Best Pipeline Ever
  • Remegen Co Ltd (9995.HK) 22H1 – Mr. Market’s “Misjudgment” Brings Opportunities to Make Money
  • Access Bio (950130 KS): COVID-19 Rapid Tests Demand Lose Sheen Sending Share Prices Down to Lows

Nexon (3659) | The Best Pipeline Ever

By Mark Chadwick

  • Nexon’s stock price is down -20% from the highs made in April and -30% from its highs last year.
  • Nexon is a key beneficiary of the trend to immersive virtual worlds and live game operations
  • The best pipeline in Nexon’s history will drive higher Free Cash Flows and shareholder returns

Remegen Co Ltd (9995.HK) 22H1 – Mr. Market’s “Misjudgment” Brings Opportunities to Make Money

By Xinyao (Criss) Wang

  • For RC18, it depends on whether RemeGen can seize this short period of strategic opportunities to further establish its leading position. The situation faced by RC48 is much more complex.
  • From the current situation, it’s very challenging for RemeGen to evolve into biopharma.That is to say, RemeGen’s future positioning is still likely to remain a biotech, which limits valuation expansion.
  • Even based on conservative forecast, there’s still decent upside potential. We’re bullish on RemeGen. Due to unfriendly macro, investors may need to consider the potential downside risks when going long.

Access Bio (950130 KS): COVID-19 Rapid Tests Demand Lose Sheen Sending Share Prices Down to Lows

By Tina Banerjee

  • Access Bio Inc (950130 KS) has been reporting triple-digit revenue growth since 2020, thanks to massive demand for the COVID-19 tests. The performance continued in this year too.
  • Going forward, the stellar revenue growth is not expected to be replicated as demand for COVID-19 tests looks uncertain beyond 2022. Revenue from the company’s malaria test is declining.
  • Access Bio has developed monkeypox tests. However, monkeypox does not seem be a large and attractive market opportunity, which can compensate for the revenue loss from COVID-19 tests.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Event-Driven: Raysum (8890 JP) Mystery Bidder Is a Hedge Fund – And That Makes It More Interesting and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Raysum (8890 JP) Mystery Bidder Is a Hedge Fund – And That Makes It More Interesting
  • Straits Times Index Quiddity Leaderboard Mar 23: Sembcorp/Keppel Situation Could Cause Index Changes
  • Fengxiang’s Judicial Auction Set for 10 October, Potential MGO

Raysum (8890 JP) Mystery Bidder Is a Hedge Fund – And That Makes It More Interesting

By Travis Lundy

  • Raysum Co Ltd (8890 JP) has been in a weird kind of limbo for well over a year. The Chairman/Founder resigned late last year for health reasons.
  • The company needed to take action to stay listed on TSE Standard. There was a plan to transfer 60+% of the shares to a foundation, through an odd arrangement.
  • Then a hedge fund stepped up and said “I’ll have 64% of the company at a near life-time high.” So now we have an interesting deal. And interesting potential future.

Straits Times Index Quiddity Leaderboard Mar 23: Sembcorp/Keppel Situation Could Cause Index Changes

By Janaghan Jeyakumar, CFA

  • The FTSE Straits Times Index (STI) (STI INDEX) has a quarterly rebalancing cycle with index reviews performed in March, June, September, and December every year.
  • The March and September reviews are complete index reviews while the June and December reviews are only for new listings. 
  • In this insight, we take a look at the potential index changes that can take place between now and the end of the March 2023 index review.

Fengxiang’s Judicial Auction Set for 10 October, Potential MGO

By Arun George

  • On 16 September, the administrator published the details for the auction of Shandong Fengxiang Co Ltd-H (9977 HK) controlling shareholder’s 70.92% stake in Alibaba Judicial Auction. 
  • If the auction is successful and results in any person and a group of persons acting in concert holding 30%+ of the voting rights, it will result in an MGO.
  • The base bid implies an MGO price of HK$1.563 per H Share, a 103.0% premium to the last close. The auction will be held from 10 October to 11 October.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Health Care: Mankind Pharma Ltd, Remegen Co Ltd, Jenscare Scientific, Access Bio Inc and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Mankind Pharma Pre-IPO Tearsheet
  • Remegen Co Ltd (9995.HK) 22H1 – Mr. Market’s “Misjudgment” Brings Opportunities to Make Money
  • Jenscare (宁波健世科技) Pre-IPO:  Massive Delays After Missing the Boat
  • Access Bio (950130 KS): COVID-19 Rapid Tests Demand Lose Sheen Sending Share Prices Down to Lows

Mankind Pharma Pre-IPO Tearsheet

By Ethan Aw

  • Mankind Pharma Ltd (6596876Z IN) is looking to raise about US$1bn in its upcoming India IPO. The deal will be run by Kotak, Axis Capital, IIFL Securities, Jefferies and JPM. 
  • Mankind Pharma (MK) is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various therapeutic areas, as well as several consumer healthcare products. 
  • It is mainly focused on the domestic market. 18 of its brands were among the 300 highest selling brands in the Indian Pharmaceutical Market (IPM), according to IQVIA.

Remegen Co Ltd (9995.HK) 22H1 – Mr. Market’s “Misjudgment” Brings Opportunities to Make Money

By Xinyao (Criss) Wang

  • For RC18, it depends on whether RemeGen can seize this short period of strategic opportunities to further establish its leading position. The situation faced by RC48 is much more complex.
  • From the current situation, it’s very challenging for RemeGen to evolve into biopharma.That is to say, RemeGen’s future positioning is still likely to remain a biotech, which limits valuation expansion.
  • Even based on conservative forecast, there’s still decent upside potential. We’re bullish on RemeGen. Due to unfriendly macro, investors may need to consider the potential downside risks when going long.

Jenscare (宁波健世科技) Pre-IPO:  Massive Delays After Missing the Boat

By Ke Yan, CFA, FRM

  • Jenscare, a China based structural heart disease focused medical device company, plans to raise up to USD 30m via a Hong Kong listing.
  • In our previous insight, we discussed that there have been many TAVR companies listed in Hong Kong but we think Jenscare has a differentiated portfolio.
  • In this note, we will look at updates in its latest filing and highlight massive delays in its product candidates. We also provide a quick thought on its valuation.

Access Bio (950130 KS): COVID-19 Rapid Tests Demand Lose Sheen Sending Share Prices Down to Lows

By Tina Banerjee

  • Access Bio Inc (950130 KS) has been reporting triple-digit revenue growth since 2020, thanks to massive demand for the COVID-19 tests. The performance continued in this year too.
  • Going forward, the stellar revenue growth is not expected to be replicated as demand for COVID-19 tests looks uncertain beyond 2022. Revenue from the company’s malaria test is declining.
  • Access Bio has developed monkeypox tests. However, monkeypox does not seem be a large and attractive market opportunity, which can compensate for the revenue loss from COVID-19 tests.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Industrials: Keppel Corp, WCP, CALB and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Straits Times Index Quiddity Leaderboard Mar 23: Sembcorp/Keppel Situation Could Cause Index Changes
  • WCP IPO: Order Table, Revised Terms, & Passive Flow Schedule
  • CALB IPO: What’s It Worth?

Straits Times Index Quiddity Leaderboard Mar 23: Sembcorp/Keppel Situation Could Cause Index Changes

By Janaghan Jeyakumar, CFA

  • The FTSE Straits Times Index (STI) (STI INDEX) has a quarterly rebalancing cycle with index reviews performed in March, June, September, and December every year.
  • The March and September reviews are complete index reviews while the June and December reviews are only for new listings. 
  • In this insight, we take a look at the potential index changes that can take place between now and the end of the March 2023 index review.

WCP IPO: Order Table, Revised Terms, & Passive Flow Schedule

By Sanghyun Park

  • WCP’s institutional subscription rate was 33.28 to 1, one of the lowest for an IPO this size. And nearly all orders sit below the lower end.
  • WCP set the price at ₩60,000, even lower than the floor, at an implied market cap of ₩2T. And the issuer also reduced the offering volume from 9M to 7.2M. 
  • Passive flows equivalent to about 3% of SO will likely flow into WCP by March next year. It is substantial enough to consider designing a flow trade setup.

CALB IPO: What’s It Worth?

By Arun George


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Financials: Raysum Co Ltd, Onewo Space-Tech, China SCE and more

By | Daily Briefs, Financials

In today’s briefing:

  • Raysum (8890 JP) Mystery Bidder Is a Hedge Fund – And That Makes It More Interesting
  • Onewo Space-Tech IPO Valuation Analysis
  • Morning Views Asia: China SCE, Country Garden Holdings Co

Raysum (8890 JP) Mystery Bidder Is a Hedge Fund – And That Makes It More Interesting

By Travis Lundy

  • Raysum Co Ltd (8890 JP) has been in a weird kind of limbo for well over a year. The Chairman/Founder resigned late last year for health reasons.
  • The company needed to take action to stay listed on TSE Standard. There was a plan to transfer 60+% of the shares to a foundation, through an odd arrangement.
  • Then a hedge fund stepped up and said “I’ll have 64% of the company at a near life-time high.” So now we have an interesting deal. And interesting potential future.

Onewo Space-Tech IPO Valuation Analysis

By Douglas Kim

  • Onewo Space-Tech (ONEWO HK) has provided its IPO price range of HK$47.1 to HK$52.7 a piece in the IPO offering of 116.74 million shares, representing 10% of its outstanding shares.
  • Our base case valuation of Onewo Spacetech is HKD27.7 per share, which represents 41% lower than the low end of the IPO price of HKD47.1 per share. 
  • Our valuation analysis suggests a range of HKD25 per share to HKD33.5 per share. We would AVOID this deal due to the much lower target price relative to IPO price.

Morning Views Asia: China SCE, Country Garden Holdings Co

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Consumer: Leapmotor, Shandong Fengxiang Co Ltd-H, Tokyo Stock Exchange Tokyo Price Index Topix, EbixCash and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Leapmotor IPO – Peers Recent Down Move Won’t Help
  • Leapmotor IPO: Valuation Insights
  • Leapmotor IPO: Stuck in the Middle
  • Fengxiang’s Judicial Auction Set for 10 October, Potential MGO
  • Effective Share-Buyback Require Proven Track Record and Communication to Gain Investor Understanding
  • EbixCash Pre-IPO – The Positives – The Few that There Are: Diversified Offering, Fast Revenue Growth

Leapmotor IPO – Peers Recent Down Move Won’t Help

By Sumeet Singh

  • Leapmotor (LM) aims to raise around US$1.0bn in its Hong Kong IPO. LM is a smart EV company based in China, founded in 2015.
  • As of end Jun 22, it had delivered a total of 104,829 cars with most of its sales coming from its mini units, T03.
  • In this note, we will run the deal through our ECM framework and talk about valuations.

Leapmotor IPO: Valuation Insights

By Arun George


Leapmotor IPO: Stuck in the Middle

By Shifara Samsudeen, ACMA, CGMA

  • Leapmotor (2007699D HK) is a leading smart EV company in China that designs and builds EVs. The company develops key hardware, software and all electronic components of the vehicles internally.
  • The company has filed for an IPO on the HKEx and plans to raise about US$1bn through the IPO.
  • In this insight, we analyse the company’s financials to understand the key reason behind the absence of gross profit margins compared to other players in the market.

Fengxiang’s Judicial Auction Set for 10 October, Potential MGO

By Arun George

  • On 16 September, the administrator published the details for the auction of Shandong Fengxiang Co Ltd-H (9977 HK) controlling shareholder’s 70.92% stake in Alibaba Judicial Auction. 
  • If the auction is successful and results in any person and a group of persons acting in concert holding 30%+ of the voting rights, it will result in an MGO.
  • The base bid implies an MGO price of HK$1.563 per H Share, a 103.0% premium to the last close. The auction will be held from 10 October to 11 October.

Effective Share-Buyback Require Proven Track Record and Communication to Gain Investor Understanding

By Aki Matsumoto

  • In my previous analysis, I found that firms with high frequency of share repurchase cancellations increased their market capitalization during the relevant period (12/2021-1/2022).
  • Even though the short-term share price performances of companies that announced share repurchases were mixed, the share prices of companies with track record of several share repurchases have risen.
  • It takes certain amount of time for investors to understand the track record and the capital allocation policy is consistent with the goal of increasing corporate value over the-long run.

EbixCash Pre-IPO – The Positives – The Few that There Are: Diversified Offering, Fast Revenue Growth

By Sumeet Singh

  • EbixCash (EC) is looking to raise around US$800m in its upcoming India IPO. The deal will be run by Motilal, Equirus, ISec, SBI Caps and Yes Securities.
  • EC is a provider of digital products and services in the B2C, B2B and financial technology arena. Its has four primary business segments: Payment solutions, travel, financial technologies and BPO.
  • In this note, we talk about the positive aspects of the deal.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars